Jiangsu Nhwa Pharmaceutical Co Ltd
Research Jiangsu Nhwa Pharmaceutical Co Ltd (002262.SZ) on Bullrun: market cap CNY 21.70B, P/E 19.7, dividend yield 1.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker002262.SZ
- ExchangeSZ
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCNY
- Market capCNY 21.70B
- P/E19.7
- Dividend yield1.9%
- Financial periodQ2 2026
- RevenueCNY 1.61B
- Net incomeCNY 423.27M
- Free cash flowCNY 45.80M
- Gross margin76.8%
Valuation Snapshot
latest market cap is CNY 21.70B; P/E is 19.7; dividend yield is 1.9%.
Peer valuation comparison
Latest P/E is 19.65x versus a Healthcare sector median of 21.75x (9.6% below).
Latest dividend yield is 1.87% versus a Healthcare sector median of 2.4% (22.1% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | CNY 21.70B | 19.7 | 1.9% | 0.4 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.4 CNY, yield 1.9%.
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Jiangsu Nhwa Pharmaceutical Co Ltd's market cap?
Jiangsu Nhwa Pharmaceutical Co Ltd's market capitalization is CNY 21.70B.
What is Jiangsu Nhwa Pharmaceutical Co Ltd's P/E ratio?
Jiangsu Nhwa Pharmaceutical Co Ltd's price-to-earnings (P/E) ratio is 19.7.
Does Jiangsu Nhwa Pharmaceutical Co Ltd pay a dividend?
Jiangsu Nhwa Pharmaceutical Co Ltd has a dividend yield of 1.9%.
What does Jiangsu Nhwa Pharmaceutical Co Ltd do?
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases.